Nuvation Bio Inc NUVB Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Sep 21, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

53,000

Price:

$1.36
Sep 20, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

117,100

Price:

$1.36
Sep 19, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,143,000

Price:

$1.26
May 15, 2023 (filed on May 17, 2023)

Insider Name:

Welch Daniel G

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

366,744

Price:

--

Filings by filing date

Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Nov 27, 2023 (filed on Nov 27, 2023)

Insider Name:

Makunje Moses

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Sep 21, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

53,000

Price:

$1.36
Sep 20, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

117,100

Price:

$1.36
Sep 19, 2023 (filed on Sep 22, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,143,000

Price:

$1.26
Feb 21, 2023 (filed on Sep 21, 2023)

Insider Name:

Nodelman Oleg

Ownership Type:

Indirect Ownership

Securities:

Class A Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

53,000

Price:

$1.36

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	357 Tehama Street, Floor 3 SAN FRANCISCO CA 94103
Tel:	1-212-6001902
Website:	https://www.nuvationbio.com
IR:	See website

Key People

David T. Hung President, Chief Executive Officer, Founder, Director	Moses Makunje Principal Accounting Officer, Principal Financial Officer	Stacy Markel Chief People Officer
Gary Hattersley Chief Scientific Officer	David Hanley Chief Technical Operations Officer	David Liu Chief Medical Officer
Kerry A. Wentworth Chief Regulatory Officer

Business Overview

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company's clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. It has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Financial Overview

For the nine months ended 30 September 2023, Nuvation Bio Inc revenues was not reported. Net loss decreased 26% to $62M. Lower net loss reflects Research & Development Expense decrease of 26% to $49.2M (expense), Interest income increase from $3.9M to $17.6M (income), General and administrative decrease of 19% to $14M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.28.

Employees:	53 as of Sep 30, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$0.00M as of Sep 30, 2023
EBITDA (TTM):	-$95.71M as of Sep 30, 2023
Net annual income (TTM):	-$82.86M as of Sep 30, 2023
Free cash flow (TTM):	-$69.26M as of Sep 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	219,944,053 as of Oct 27, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization